Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2090275
Abstract: Abstract Objective Project NORTH compared real-world clinical and economic outcomes in Swedish patients with inflammatory bowel disease (IBD) who switched from originator infliximab to its biosimilar. Materials and methods Data from electronic medical records and… read more here.
Keywords: disease; non switchers; originator infliximab; infliximab biosimilar ... See more keywords
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-214374
Abstract: To date, all available data regarding the switch from bio-originator to its biosimilar are reassuring, and the switch has been recommended as a shared patient–physician decision in recent consensus-based recommendations.1 In particular, the Norway's infliximab… read more here.
Keywords: originator; long term; term follow; originator infliximab ... See more keywords
Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
Sign Up to like & getrecommendations! Published in 2022 at "Gut and Liver"
DOI: 10.5009/gnl220005
Abstract: Background/Aims The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861). We performed a multivariate logistic analysis to demonstrate the association between early infliximab trough… read more here.
Keywords: trough levels; infliximab; infliximab trough; week ... See more keywords